Best Practices for the Implementation of Clinical Advances in HR-Positive/HER2-Negative Breast Cancer

Experts discuss current and emerging oral targeted therapies in early and advanced HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Allison Butts, PharmD, BCOP Kristina F. Byers, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 3, 2022 Expired: May 2, 2023

Commentary on advances in oral targeted therapies for the treatment of early and metastatic breast cancer, adverse event management, and tools for adherence, from Clinical Care Options (CCO)

Allison Butts, PharmD, BCOP Kristina F. Byers, PharmD, BCOP Released: April 25, 2022